Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Laura Royo
Observed names:
L. Royo,
Royo, Laura
Institution:
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Observed institutions:
Cork University Hospital,
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol,
Institute of Predictive and Personalized Medicine of Cancer
ORCID:
0000-0001-5770-2001
Observed ORCID:
0000-0001-5770-2001
OpenAlex ID:
A5024209538
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications
2020
·
Juan Carrillo-Reixach
, Laura Torrens
, et al.
·
Journal of Hepatology
·
159
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response
2023
·
Mario Failli
, Salih Demir
, et al.
·
Hepatology
·
20
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2023
·
Jordi Abril-Fornaguera
, Laura Torrens
, et al.
·
Molecular Cancer Therapeutics
·
20
PDF
MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines
2022
·
David Corujo
, Roberto Malinverni
, et al.
·
Cell Reports
·
15
PDF
Characterisation of Aberrant Metabolic Pathways in Hepatoblastoma Using Liquid Chromatography and Tandem Mass Spectrometry (LC-MS/MS)
2023
·
Alison Whitby
, Pardeep Pabla
, et al.
·
Cancers
·
6
PDF
Unpublished Mediterranean records of marine alien and cryptogenic species
2020
·
Karachle, Paraskevi K.
, Yapici, Sercan
, et al.
·
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
·
2
EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma
2026
·
Fatma Zohra Khoubai
, Alexia Calovoulos
, et al.
·
Molecular Cancer
EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma
2026
·
Khoubai, Fatma Zohra
, Calovoulos, Alexia
, et al.
·
Figshare
7 - Integrative Proteomics Uncovers Shared Molecular Programs in Pediatric and Adult Liver Cancer Related to Patient Outcome
2026
·
Queralt Miñarro-Ribot
, Maria Torner
, et al.
·
Gastroenterología y Hepatología
Supplementary Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2025
·
Jordi Abril-Fornaguera
, Laura Torrens
, et al.
FRI-466-YI Implications and therapeutic potential of neddylation for pediatric liver cancer: hepatoblastoma
2024
·
Leidy Estefanía Zapata-Pavas
, Marina Serrano-Macía
, et al.
·
Journal of Hepatology
Impact of next generation sequencing in high grade glioma management.
2024
·
Simon Barry
, Yazan Hani Mustafa
, et al.
·
Journal of Clinical Oncology
Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2023
·
Jordi Abril-Fornaguera
, Laura Torrens
, et al.
Supplementary Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2023
·
Jordi Abril-Fornaguera
, Laura Torrens
, et al.
Supplementary Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2023
·
Jordi Abril-Fornaguera
, Laura Torrens
, et al.
Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2023
·
Jordi Abril-Fornaguera
, Laura Torrens
, et al.
Supplementary Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2023
·
Jordi Abril-Fornaguera
, Laura Torrens
, et al.
Development of Hepatoblastoma organoids as a patient-derived ex-vivo system
2022
·
Laura Zanatto
, Paula Cantallops Vilà
, et al.
·
Journal of Hepatology
Precision medicine targeting disrupted IGF signaling in hepatoblastoma
2018
·
O. Kuchuk
, N. Akers
, et al.
·
Journal of Hepatology
Show more works
View as search
Works count:
21
Citation count:
222
H-index:
5
I10-index:
4
Year
Topic
Type